# US 2022/0031630 A1 · Nanoparticle formulations and methods of their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031630 A1
- Document ID: US20220031630A1
- Status: Published application
- Kind: A1
- Application number: 17/275,266
- Filed: 2019-09-13
- Published: 2022-02-03
- Earliest claimed: 2018-09-13
- Assignees: The Brigham and Women's Hospital, Inc.; Massachusetts Institute of Technology; Children's Medical Center Corporation
- Applicants: The Brigham and Women's Hospital, Inc.; Massachusetts Institute of Technology; Children's Medical Center Corporation
- Inventors: Jeffrey M. KARP; Wen LI; Nitin JOSHI; Robert S. LANGER; Rebekah MANNIX; Jianhua QIU; Sezin ADAY
- Web page: https://patentgrep.com/patent/US20220031630A1

## CPC

- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/063: {Glutathione}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are pharmaceutical compositions formulated for delivery to the brain of a subject. The compositions include a plurality of nanoparticles (NPs) containing a brain therapeutic agent, poly(lactic-co-glycolic acid) (PLGA), and a pharmaceutically acceptable excipient selected from the group consisting of a surfactant, peptide, and combinations thereof. Also disclosed are methods of their use.

## Claims

### Claim 1

A pharmaceutical composition formulated for delivery to the brain of a subject, the composition comprising a plurality of nanoparticles (NPs) comprising a brain therapeutic agent, poly(lactic-co-glycolic acid) (PLGA), and a pharmaceutically acceptable excipient selected from the group consisting of a surfactant, peptide, and combinations thereof.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the brain therapeutic agent treats a functional disorder.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the brain therapeutic agent treats a physical disorder.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the physical disorder is a traumatic brain injury.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a surfactant.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the surfactant is a polysorbate, polyethylene glycol, or poloxamer.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the surfactant is a polysorbate.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the polysorbate is polysorbate 80.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises 0.001-0.2% (w/v) of the surfactant.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises 0.1-0.2% (w/v) of the surfactant.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a peptide.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein the peptide is glutathione, transferrin, or a combination thereof.

### Claim 14 (depends on 12)

The pharmaceutical composition of claim 12, wherein the peptide is glutathione.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises 0.05-0.5% (w/v) of the peptide.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises 0.1-0.2% (w/v) of the peptide.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, wherein the NPs have an average hydrodynamic diameter of 40-150 nm, as measured by Dynamic Light Scattering.

### Claim 18 (depends on 1)

The pharmaceutical composition of claim 1, wherein the NPs have an average hydrodynamic diameter of 40-100 nm, as measured by Dynamic Light Scattering.

### Claim 19 (depends on 1)

The pharmaceutical composition of claim 1, wherein the NPs have an average hydrodynamic diameter of 55-95 nm, as measured by Dynamic Light Scattering.

### Claim 20 (depends on 1)

The pharmaceutical composition of claim 1, wherein the average molecular weight of the NPs is 7-31 kDa.

### Claim 21 (depends on 1)

The pharmaceutical composition of claim 1, wherein the average diameter of the NPs is 40-70 nm, as measured by transmission electron microscopy (TEM).

### Claim 22 (depends on 1)

The pharmaceutical composition of claim 1, wherein the brain therapeutic agent is a nucleic acid.

### Claim 23 (depends on 22)

The pharmaceutical composition of claim 22, wherein the nucleic acid is a plasmid, siRNA, shRNA, miRNA, antisense oligonucleotide, gRNA, aptamer, or a combination thereof.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, wherein the nucleic acid is siRNA or antisense oligonucleotide.

### Claim 25 (depends on 1)

The pharmaceutical composition of claim 1, wherein the brain therapeutic agent is selected from the group consisting of anti-inflammatory drugs, steroids, antibiotics, immunosuppressants, chemotherapeutics, sensitizing agents, antibodies, antibody fragments, proteins, peptides, growth factors, cytokines, cells, stem cells, vitamins, and combinations thereof.

### Claim 26 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a solvent.

### Claim 27 (depends on 23)

The pharmaceutical composition of claim 23, wherein the solvent is water, saline, or phosphate-buffered saline.

### Claim 28 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises 0.5-50 mg/mL of PLGA.

### Claim 29 (depends on 1)

A method of delivering a brain therapeutic agent to a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 1.

### Claim 30 (depends on 29)

The method of claim 29, wherein the method treats a functional disorder in the subject,

### Claim 31 (depends on 30)

The method of claim 30, wherein the functional disorder is a mental disorder.

### Claim 32 (depends on 30)

The method of claim 30, wherein the functional disorder is a physical disorder.

### Claim 33 (depends on 32)

The method of claim 32, wherein the physical disorder is a traumatic brain injury.

### Claim 34 (depends on 30)

The method of claim 30, wherein the functional disorder is a traumatic brain injury and the brain therapeutic agent is a nucleic acid.

### Claim 35 (depends on 29)

The method of claim 29, wherein the pharmaceutical composition is administered intravenously.

### Claim 36

A pharmaceutical composition comprising a plurality of nanoparticles (NPs) comprising a cargo molecule, a hydrophobic polymer, and a pharmaceutically acceptable excipient selected from the group consisting of a surfactant, peptide, and combinations thereof.

### Claim 37 (depends on 36)

The pharmaceutical composition of claim 36, wherein the pharmaceutical composition comprises a surfactant.

### Claim 38 (depends on 36)

The pharmaceutical composition of claim 36, wherein the surfactant is a polysorbate, polyethylene glycol, or poloxamer.

### Claim 39 (depends on 38)

The pharmaceutical composition of claim 38, wherein the surfactant is a polysorbate.

### Claim 40 (depends on 39)

The pharmaceutical composition of claim 39, wherein the polysorbate is polysorbate 80.

### Claim 41 (depends on 36)

The pharmaceutical composition of claim 36, wherein the pharmaceutical composition comprises 0.001-0.2% (w/v) of the surfactant.

### Claim 42 (depends on 36)

The pharmaceutical composition of claim 36, wherein the pharmaceutical composition comprises 0.1-0.2% (w/v) of the surfactant.

### Claim 43 (depends on 36)

The pharmaceutical composition of claim 36, wherein the pharmaceutical composition comprises a peptide.

### Claim 44 (depends on 36)

The pharmaceutical composition of claim 36, wherein the peptide is glutathione, transferrin, or a combination thereof.

### Claim 45 (depends on 44)

The pharmaceutical composition of claim 44, wherein the peptide is glutathione.

### Claim 46 (depends on 36)

The pharmaceutical composition of claim 36, wherein the pharmaceutical composition comprises 0.05-0.5% (w/v) of the peptide.

### Claim 47 (depends on 36)

The pharmaceutical composition of claim 36, wherein the pharmaceutical composition comprises 0.1-0.2% (w/v) of the peptide.

### Claim 48 (depends on 36)

The pharmaceutical composition of claim 36, wherein the NPs have an average hydrodynamic diameter of 40-150 nm, as measured by Dynamic Light Scattering.

### Claim 49 (depends on 36)

The pharmaceutical composition of claim 36, wherein the NPs have an average hydrodynamic diameter of 40-100 nm, as measured by Dynamic Light Scattering.

### Claim 50 (depends on 36)

The pharmaceutical composition of claim 36, wherein the NPs have an average hydrodynamic diameter of 55-95 nm, as measured by Dynamic Light Scattering.

### Claim 51 (depends on 36)

The pharmaceutical composition of claim 36, wherein the average molecular weight of the NPs is 7-31 kDa.

### Claim 52 (depends on 36)

The pharmaceutical composition of claim 36, wherein the average diameter of the NPs is 40-70 nm, as measured by transmission electron microscopy (TEM).

### Claim 53 (depends on 36)

The pharmaceutical composition of claim 36, wherein the cargo molecule is a nucleic acid, an anti-inflammatory drug, a steroid, an antibiotic, an immunosuppressant, a chemotherapeutic, a sensitizing agent, an antibody or fragment thereof, a protein or peptide, a growth factor, a cytokine, a cell, a vitamin, or any combination of the foregoing cargoes.

### Claim 54 (depends on 36)

The pharmaceutical composition of claim 36, wherein the pharmaceutical composition comprises a solvent.

### Claim 55 (depends on 54)

The pharmaceutical composition of claim 54, wherein the solvent is water, saline, or phosphate-buffered saline.

### Claim 56 (depends on 36)

The pharmaceutical composition of claim 36, wherein the hydrophobic polymer is a biodegradable hydrophobic polymer.

### Claim 57 (depends on 36)

The pharmaceutical composition of claim 36, wherein the hydrophobic polymer is poly(lactic-co-glycolic acid) (PLGA), poly(caprolactone) (PCL), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(caprolactone)-co-poly(lactic acid) (PCLLA), poly(L-lactic acid) (PLLA), or poly(glycerol sebacate) acrylate (PGSA).

### Claim 58 (depends on 36)

The pharmaceutical composition of claim 36, wherein the hydrophobic polymer is PLGA.

### Claim 59 (depends on 36)

The pharmaceutical composition of claim 36, wherein the pharmaceutical composition comprises 0.5-50 mg/mL of the hydrophobic polymer.
